BACKGROUND: Prior studies have reported mixed results regarding relationships between vitamin D, androgens, and sex hormoneebinding globulin in patients with polycystic ovary syndrome. However, less is known regarding these associations in eumenorrheic, premenopausal women. OBJECTIVE: Our objective was to study the relationships between serum vitamin D and androgen biomarkers in eumenorrheic women with a history of pregnancy loss who were attempting pregnancy. STUDY DESIGN: This was an analysis of a cohort of 1191 participants from the Effects of Aspirin in Gestation and Reproduction trial (2006e2012). Participants were attempting to conceive, aged 18e40 years, with 1e2 documented prior pregnancy losses and no history of infertility, and recruited from 4 academic medical centers in the United States. Serum vitamin D (25-hydroxyvitamin D) and hormone concentrations were measured at baseline.
A lthough vitamin D is well known for its effects on bone health and metabolism, it is also associated with a host of reproductive outcomes [1] [2] [3] and has receptors in the ovary, uterus, placenta, hypothalamus, and pituitary gland. [4] [5] [6] Additionally, the vitamin has been implicated in a number of pathologies affecting women, 7, 8 including polycystic ovary syndrome (PCOS), [9] [10] [11] yet little is known about how it affects androgen homeostasis in premenopausal, eumenorrheic women.
Studies have linked serum vitamin D to serum testosterone and sex hormoneebinding globulin (SHBG) concentrations in populations of postmenopausal women and premenopausal women with PCOS, [12] [13] [14] but none have investigated this relationship in premenopausal, regularly cycling women. The SHBG data gap is especially important, given its role in binding freely circulating steroid hormones, including androgens, and thereby limiting their biological availability. 15 Exploring the normal physiological relationship between vitamin D, SHBG, and androgens in eumenorrheic, premenopausal women may help us better understand the role vitamin D plays in the pathophysiology of androgen excess and shed light on future strategies to address it. Therefore, we aimed to evaluate the relationship between vitamin D and androgen biomarkers in a large cohort of eumenorrheic, premenopausal women with a prior pregnancy loss.
Materials and Methods
This is a cohort from the Effects of Aspirin in Gestation and Reproduction (EAGeR) trial, which was a multicenter, block-randomized, double-blind, placebo-controlled trial of daily low-dose aspirin (81 mg) in 1228 women recruited from 4 US medical centers from 2007 to 2011. Institutional review board approval was obtained at each study site and the data coordinating center. All participants provided written informed consent. The trial was registered with ClinicalTrials. gov, number NCT00467363. Full details of the study design, methods, and participant characteristics have been published elsewhere. 16 
Study design and population
Women attempting conception, aged 18e40 years, with regular menstrual cycles of 21e42 days in length, with documented confirmation of 1 or 2 prior pregnancy losses, and up to 2 prior live births were eligible for the EAGeR trial. 16 Exclusion criteria for all women included clinical indication for use of anticoagulant therapy or chronic use of nonsteroidal antiinflammatory drugs; major medical disorders (eg, diabetes, hypertension, etc); and any prior diagnosis of infertility or subfertility 
Study procedures
Participants attended a prerandomization, baseline study visit timed to occur around day 2e4 of their menstrual cycle. During this baseline visit, participants completed questionnaires of reproductive health status, demographic, and lifestyle factors. In addition, anthropometric measures and blood samples were collected. Samples were centrifuged and serum and plasma were aliquoted and frozen within 90 minutes. Samples were stored at e80 C until analysis.
Biochemical analysis
Primary outcomes for the present analysis were baseline serum concentrations of total testosterone, free testosterone, free androgen index, SHBG, and dehydroepiandrosterone sulfate (DHEAS concentrations were measured in serum using the 25(OH)D ELISA solid-phase sandwich enzyme immunoassay (BioVendor R&D, Ashville, NC). The interassay laboratory CVs were 15.8% and 13.1% at mean concentrations of 15.5 and 41.6 ng/mL, respectively, for lyophilized manufacturer's controls and 17% for an in-house pooled serum control. The lower limit of detection was 1.6 ng/mL, and all values were above this limit.
Statistical analysis
Participants were determined to be vitamin D sufficient ( All models were adjusted for age, body mass index (BMI), smoking status, race, income, education, physical activity, and season of blood draw. Models for SHBG were additionally adjusted for TT, mean follicular-phase E1G, and insulin because they are known to affect SHBG concentrations. 20 Models were not adjusted for treatment arm because blood samples were collected before treatment.
All analyses were run using both categorical vitamin D status (sufficient vs insufficient vs deficient) and continuous vitamin D concentrations. Assumptions AJOG at a Glance Why was this study conducted? To study the relationships between serum vitamin D and androgen biomarkers in eumenorrheic women with a history of pregnancy loss who were attempting pregnancy.
What are the key findings? Vitamin D is negatively associated with the bioavailability of androgens and positively associated with sex hormoneebinding globulin concentrations.
What does this study add to what is already known?
This study extends previous work in women with polycystic ovary syndrome and postmenopausal women to evaluate the role of vitamin D and androgen biomarkers in a population of eumenorrheic women with a history of pregnancy.
ajog.org GYNECOLOGY Original Research of linearity were tested using restricted cubic splines and sensitivity analyses, excluding patients with vitamin D above the 99th percentile, and controlling for vitamin supplement intake were evaluated. SAS version 9.4 (SAS Institute, Cary, NC) was used for all statistical analysis.
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Results
Vitamin D data were available for 1191 patients. The median vitamin D concentration was 29.1 ng/mL (interquartile range, 23.1e36.0) and concentrations ranged overall from 5.0 to 143.6 ng/mL. With regard to race, a higher proportion of vitamin Desufficient women were white than vitamin Deinsufficient and edeficient women (Table 1) . Vitamin Desufficient participants also had lower BMI and smaller waist circumference, sum of skinfolds, and central-to-peripheral skinfold ratio than their vitamin Deinsufficient and edeficient counterparts.
Vitamin D was associated with neither TT nor DHEAS ( 
Comment
Our results show increasing vitamin D concentrations were negatively associated with FAI and positively associated with SHBG in this cohort of eumenorrheic women with history of prior pregnancy loss who were attempting pregnancy. Overall, our results help elucidate the role vitamin D may play in the bioavailability of androgens, a potential factor in the pathophysiology of hyperandrogenism and its related complications for women of reproductive age. The magnitude of the changes in our population of eumenorrheic women was approximately 10%, although the long-term effects of these changes in hormone concentrations on other reproductive outcomes is unknown.
To our knowledge, this is the first comprehensive analysis of the relationship between vitamin D and androgens among eumenorrheic, regularly cycling women. Studies of other populations have shown a positive relationship between vitamin D and TT in normal-BMI patients with PCOS 12 and a negative relationship among postmenopausal women. 13 A systematic review and metaanalysis of vitamin D supplementation among a total of 183 women with PCOS found that supplementation with vitamin D significantly reduces TT. 21 Our null results may differ from these studies because our population was, respectively, eumenorrheic, premenopausal, and not being supplemented with vitamin D.
With regard to the bioavailability of testosterone, the largest study to date demonstrated a negative relationship between vitamin D and fT among postmenopausal women, 14 which is consistent with our findings. With regard to SHBG, the positive relationship with vitamin D concentration that we observed is consistent with results observed previously among both women with PCOS 22, 23 and postmenopausal women.
14,24 However, our positive finding conflicts with results from the aforementioned meta-analysis; 21 our study's larger cohort (and therefore greater power) may also explain why we found a relationship between vitamin D and SHBG while the meta-analysis did not.
In addition, the present study included a predominantly nonobese population without diagnosed PCOS; it is plausible that differences in obesity prevalence, and accordingly insulin resistance, could perhaps have an impact on the relationship between vitamin D and SHBG.
Prior research supports a strong biological rationale for the association between vitamin D and hyperandrogenic states, mediated through vitamin D receptor (VDR) polymorphisms. Different VDR polymorphisms have been linked to an increased risk of having PCOS, 25 increased severity of PCOS, 26 and higher testosterone and androstenedione concentrations than patients with other VDR polymorphisms. 27 VDR polymorphism Bsm-I is specifically associated with lower SHBG concentrations, 28 providing a potential mechanism for vitamin D to affect the bioavailability of androgens as we see in this study. If vitamin D does in fact influence SHBG homoeostasis, then TT could remain unchanged while bioavailability would increase, therefore raising the potential for women to suffer from the physical effects of elevated androgens while having clinically normal total concentrations.
Our study is unique in that it evaluated androgen outcomes in eumenorrheic premenopausal women with prior pregnancy loss, whereas prior studies assessed the relationship of vitamin D with either women diagnosed with PCOS or postmenopausal women. Because 92.4% of participants in the trial were taking some sort of vitamin supplement and we do not have data on dietary intake or vitamin contents, it is possible that some patients were consuming supplemental vitamin D for which we were unable to account. However, serum concentrations have been shown to be an accurate biological reflection of vitamin D status, 29, 30 regardless of source, so we believe these markers should be relevant markers of vitamin D status, To our knowledge, this is the first study to elucidate the positive relationship of vitamin D with SHBG and negative relationship with the FAI in eumenorrheic, premenopausal women with prior pregnancy loss. Because vitamin D and SHBG interact in other diseases, it is plausible that vitamin D status may affect SHBG concentrations and subsequently the bioavailability of androgens, although we were limited in assessing the directionality of the associations, given the cross-sectional nature of our study. Overall, these findings shed light on a potential pathological process and spurs the need for prospective studies regarding vitamin D and its potential role in addressing androgen excess. n
